GPE
Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy
Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data
CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile
CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection
Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###
Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs
Takeda Announces 641 Layoffs in Massachusetts Amid $900 Million Restructuring Campaign
Takeda, layoffs, Massachusetts, restructuring, pharmaceuticals, biotech, Cambridge, Lexington
Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success
Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study
AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China
AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.
Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift
Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events
Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations
AbbVie’s Skyrizi and Rinvoq Drive Growth, Counteracting Humira Decline
AbbVie, Skyrizi, Rinvoq, Humira, full-year outlook, pharmaceutical industry, revenue growth, drug sales, immunology drugs
Shimadzu Corporation Expands US Presence with Three New R&D Centers for Pharmaceutical Growth
Shimadzu Corporation, R&D centers, US expansion, pharmaceutical industry, business growth, innovation, technology.